Evaluation of pneumococcal and tetanus vaccine responses in patients with rheumatoid arthritis receiving baricitinib: results from a long-term extension trial substudy

BACKGROUND: Clinical guidelines recommend pneumococcal and tetanus vaccinations in patients with rheumatoid arthritis (RA). Baricitinib is an oral, selective Janus kinase (JAK) 1/JAK 2 inhibitor and is approved for the treatment of moderately to severely active RA in adults in over 50 countries incl...

Descripción completa

Detalles Bibliográficos
Autores principales: Winthrop, Kevin L., Bingham, Clifton O., Komocsar, Wendy J., Bradley, John, Issa, Maher, Klar, Rena, Kartman, Cynthia E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6471863/
https://www.ncbi.nlm.nih.gov/pubmed/30999933
http://dx.doi.org/10.1186/s13075-019-1883-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6471863/
https://www.ncbi.nlm.nih.gov/pubmed/30999933
http://dx.doi.org/10.1186/s13075-019-1883-1

Ejemplares similares